Repatha evolocumab regulatory update

FDA approved the Repatha Pushtronex system to deliver a once-monthly 420 mg subcutaneous dose of Amgen’s Repatha evolocumab to treat patients

Read the full 219 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE